Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivastigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 0.90 |
| ▸ | BCHE known ✓ | P06276 | 11/20 | 0.90 |
| ▸ | FAAH | O00519 | 1/20 | 0.90 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.82 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivastigmine SCHEMBL29614698 | 0.95 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL2764 | 0.95 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL1170429 | 0.95 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL6382107 | 0.95 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL13841811 | 0.95 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL6382629 | 0.95 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL5803794 | 0.94 | ACHE (0.97) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL16568160 | 0.94 | ACHE (0.97) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL916695 | 0.94 | ACHE (0.97) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL25232361 | 0.90 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2021026429-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20150217004-A1 | CARBAMATE COMPOUNDS AND METHODS OF USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION | 2015-08-06 | — | — | US | disclosed |
| WO-2014039526-A2 | CARBAMATE COMPOUNDS AND METHODS OF USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150217004-A1 | CARBAMATE COMPOUNDS AND METHODS OF USE IN DISEASES OF THE NERVOUS SYSTEM | CHAT, ACHE, HCRTR1 | ACHE 2/4885BCHE 4/4885FAAH 81/4885 |
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | BCHE, ACHE, CHAT | ACHE 2/4885BCHE 1/4885FAAH 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.